Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients With Type 2 Diabetes

X
Trial Profile

A Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients With Type 2 Diabetes

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ninerafaxstat (Primary)
  • Indications Diabetic cardiomyopathy; Heart failure
  • Focus Proof of concept; Therapeutic Use
  • Acronyms IMPROVE-DiCE
  • Sponsors Imbria Pharmaceuticals
  • Most Recent Events

    • 29 Aug 2022 Results assessing the effects of ninerafaxstat - a novel cardiac mitotrope designed to shift myocardial substrate utilisation in favour of glucose and thus, restore myocardial energy homeostasis - on cardiac metabolism & diastolic function in patients with type-2 diabetes and obesity, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
    • 26 Aug 2022 According to an Imbria Pharmaceuticals media release, data from this trial were presented at the upcoming European Society of Cardiology (ESC) Congress, 2022.
    • 26 Aug 2022 Results published in an Imbria Pharmaceuticals Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top